John Newman

​The field of longevity has long been considered to be theoretical and one for the future, but that future is here now. The science of ketosis promises lucrative opportunities in a wide range of therapeutic areas, and the global keto market is expected to rise to $15 billion by 2027.

Juvenescence has brought together the leading experts in the ketone metabolism research field for a panel discussion on the revolution happening with ketones and the direction the research is leading the key players in this space. We cover how ketones can modulate fundamental aspects of human physiology, including glucose metabolism, brain function and heart health.

Juvenescence was founded with a mission to transform what aging means to the world. Science around aging is accelerating at an extraordinary pace so we’ve set out to further that science through a coalition of the best scientists, physicians and investors creating cutting-edge therapies and products that will empower people to chart their own path forward. Our company represents a modality-agnostic portfolio of therapies developed by seasoned drug developers augmented by machine learning. We have raised over $200MM to date and are organized around two major divisions: JuvRx (Drug Therapies) and JuvLife (NonRx IP-protected and clinically-studied food ingredients and dietary supplements).

Get the experts’ insights on the latest research and development, hear from our founders, Dr. Greg Bailey and Jim Mellon on the opportunity areas in the market.